Skip to content

Site logo

Main menu
  • Company
    • Company overview
    • Stories
    • History
    • Environmental, Social & Governance (ESG)
      • ESG overview
      • Philanthropy
      • Merck Medical Outreach Program
      • Impact investing
      • Transparency disclosures
      • ESG resources
    • Leadership
      • Leadership overview
      • Board of directors
      • Executive team
    • Culture & values
      • Culture & values overview
      • Code of conduct & compliance
    • Diversity & inclusion
    • Policies & positions
    • Business development & licensing
    • Suppliers
      • Suppliers overview
      • Supplier registration
      • Supplier help for Ariba
  • Research
    • Research overview
    • Our COVID-19 efforts
    • Areas of focus
      • Oncology
      • Vaccines
      • Infectious diseases
      • Cardio-metabolic disorders
    • Pipeline
    • Discovery & development
    • R&D locations
    • Clinical trials
      • Clinical trials overview
      • Find a trial
      • Diversity in clinical trials
  • Products
    • Products list
    • Product patents
    • Merck authorized distributors
  • Patients
    • Patients overview
    • Patient support programs
    • Patient resources
    • Patient & treatment education
  • Careers
    • Careers
    • Search jobs
    • Our divisions
      • Research & development
      • Manufacturing & supply
      • Human Health
      • Animal Health
      • Global support functions
    • Veterans
    • Student opportunities
    • Compensation & benefits
    • How we hire
    • MSD Careers
    • Events
    • Talent community
  • Investors
    • Investors overview
    • Events & presentations
    • Financial information
      • Financial information overview
      • SEC filings
    • Stock information
    • Investor resources
      • Investor resources overview
      • Organon resources
      • Request for information
  • Media
    • Media overview
    • News releases
    • Company statements
    • Media library & contacts
      • Media contact & library overview
      • Company fact sheet
two scientists wearing masks

Our COVID-19 efforts

Learn more
Contact us

Worldwide Countries outside of the United States and Canada.

What can we help you find?

Search for:

The status of vaccine development against the human cytomegalovirus

Post navigation

Optimization of Critical Quality Attributes in Tablet Film Coating and Design Space Determination Using Pilot-Scale Experimental Data
  • What can we help you find?

    Search for:
  • Pages

    • Careers
    • Certification of products subject to the requirements of the Consumer Product Safety Improvement Act of 2008 (CPSIA)
    • Contact us
    • Copyright
    • Forward-looking statement
    • ical
    • Merck | Home
    • Products list
      • Product patents
      • Authorized distributors
    • Sitemap
    • Stories
    • Terms of use
    • About us
      • History
      • Environmental, Social & Governance (ESG)
        • ESG resources
        • Impact investing
        • Merck Medical Outreach Program
        • Philanthropy
          • A closer look: Merck Richard T. Clark Fellowship for Global Health
          • Advancing equity in cancer care
          • Advancing patient-centered cancer care
          • Advancing patient-centered cancer care in resource-limited communities
          • Building health care capacity in India and Vietnam
          • Enhancing diabetes care through community outreach and support
          • Improving access to high-quality diabetes care
          • Improving access to HIV care in sub-Saharan Africa
          • Improving Alzheimer’s care in the U.S.
          • Promoting equity in HIV/AIDS care
          • Tackling the U.S. opioid crisis
        • Transparency disclosures
      • Leadership
        • Board of directors
        • Executive team
      • Culture & values
        • Code of conduct & compliance
          • Code of conduct – Values & standards
          • Business partner code of conduct
      • Diversity & inclusion
      • Policies & positions
      • Business development & licensing
      • Suppliers
    • Research
      • CHLOR-TRIMETON
      • CRIXIVAN®
      • CUSHION GRIP®
      • DRIXORAL
      • GYNE-LOTRIMIN®
      • MAXALT®
      • MEXSANA
      • PROSCAR
      • Singulair
      • Vaccines
      • ZOCOR® (simvastatin)
      • COVID-19
      • Infectious diseases
      • Oncology
      • Cardio-metabolic diseases
      • Pipeline
      • Discovery & development
        • Ethical treatment of animals
      • Clinical trials
      • Diversity in clinical trials
      • R&D locations
    • Patients & caregivers
      • Patient support programs
      • Patient resources
      • Patient & treatment education
    • Investor relations
      • Email alerts
      • Email alerts
      • Email alerts
      • Events & presentations
      • Financial information
        • SEC filings
      • Stock information
      • Investor resources
        • Request for information
      • Organon resources
    • Media
      • News releases
      • Company statements
      • Media library & contacts
        • Company fact sheet
      • Molnupiravir media Iibrary
  • Archives

  • Categories

    • No categories

Connect with us on social

social icon social icon social icon social icon social icon
  • MerckHelps
    Merck Patient Assistance Program provides certain Merck medicines and adult vaccines for free to qualified patients
  • Merck Access Program
    Information about insurance coverage and financial assistance options for eligible patients
  • Clinical trials
    Learn about our clinical trials and find available studies
  • Merck Manuals
    Medical information source covering thousands of topics in all fields of medicine
  • Environmental, Social & Governance (ESG) Report
    Reporting on our commitment to operating responsibly to benefit society
  • Merck for Mothers
    An initiative to create a world where no woman has to die giving life
  • Merck Animal Health
    The global animal health business unit of Merck
  • Health Plan - Transparency in Coverage
    In compliance with the Consolidated Appropriations Act, learn more about our health plan's pricing information.
  • Forward-looking statement
  • Cookie policy
  • Privacy
  • Transparency disclosure
  • Terms of use
  • Accessibility
  • Sitemap
Copyright © 2023 Merck & Co., Inc., Rahway, NJ USA, and its affiliates. All rights reserved. | This site is intended only for residents of the United States and Canada.
Accessibility icon View Privacy Shield Verification Status View APEC CBPR Privacy Certification Status

Forward-looking statement of Merck & Co., Inc., Rahway, N.J., USA

This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the recent global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2021 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

No Duty to Update
The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.

Decline Accept

You are leaving Merck.com

Continue

Welcome to Merck.com

By continuing, you will be directed to a site intended only for residents of the United States and Canada. We are called MSD everywhere, except in the United States and Canada where we are known as Merck & Co Inc, Rahway, NJ USA.

Continue